Trending >

ProMetic Life Sciences’ decision to finance is sound, says Paradigm

ProMetic Life Sciences

ProMetic Life SciencesThe decision to pull the trigger on a financing is a sound one for ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart, News: TSX:PLI), says Paradigm Capital analyst Alan Ridgeway.

This morning, ProMetic announced it had closed a previously announced bought deal that saw the company issue 13.2-million shares at $1.90 for proceeds of $25.08-million. The deal was led by Canaccord and included RBC and Beacon Securities.

Ridgeway says the financing will give ProMetic the runway to bring its large pipeline of drugs forward. The analyst reminded that resin sales can be lumpy, and that timing is simply not under ProMetic’s control.

“With >$30M of cash on hand following the raise, management now has the resources to fully fund PBI-4050’s Phase II program and the registration trials for plasminogen, AAT, IVIG and two additional products. In addition, if PBI-4050 produces positive results in any of its planned Phase II studies, PLI should be in a stronger position to partner the asset,” said Ridgeway.

In a research update to clients this morning, Ridgeway maintained his “Buy” rating and $3.10 price target on ProMetic, implying a return of 56% at the time of publication.

More Cantech Life Sciences

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.
insta twitter facebook

Comment

Leave a Reply